Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 57 clinical trials
featured
Cutaneous Squamous Cell Carcinoma

People with cutaneous squamous cell carcinoma are asked to participate in a research study being conducted by Northwell Health, Inc.  

  • 24 views
  • 23 Nov, 2020
  • 1 location
featured
CEMIPLIMAB SURVIVORSHIP EPIDEMIOLOGY (CASE) STUDY

People with cutaneous squamous cell carcinoma are asked to participate in a research study being conducted by Montefiore Medical Center.  

  • 9 views
  • 01 Aug, 2019
  • 1 location
featured
CEMIPLIMAB SURVIVORSHIP EPIDEMIOLOGY (CASE) STUDY

People with cutaneous squamous cell carcinoma are asked to participate in a research study being conducted by Monter Cancer Center.  

cancer
  • 23 views
  • 02 Aug, 2019
  • 1 location
featured
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Investigational Product in Patients With Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Investigational Product in Patients With Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)

  • 206 views
  • 08 Nov, 2020
  • 1 location
featured
Do you suffer from Hemorrhoids?

Do you suffer from Hemorrhoids?

  • 1312 views
  • 08 Nov, 2020
  • 1 location
featured
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension

A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension

  • 106 views
  • 08 Dec, 2020
  • 1 location
Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

For Groups 1 to 4, the primary objective of this study is to estimate the clinical benefit of cemiplimab monotherapy for patients with: metastatic (nodal or distant) cutaneous squamous cell

  • 0 views
  • 25 Jan, 2021
  • 101 locations
Pembrolizumab Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

This is a randomized, double-blind, study that compares pembrolizumab with placebo given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell carcinoma (LA

mk-3475
adjuvant therapy
cancer
pembrolizumab
  • 69 views
  • 18 Jan, 2021
  • 132 locations
Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study

This study will treat resectable cutaneous squamous cell carcinoma patients with pramlintide for two weeks prior to surgical resection of their tumor. Pre-treatment and surgical resection

skin cancer
solid tumors
platelet count
cancer
  • 0 views
  • 25 Jan, 2021
  • 1 location
Pre-Operative Cemiplimab Administered Intralesionally for Patients With Recurrent Cutaneous Squamous Cell Carcinoma

The primary objective is to characterize the safety and tolerability of cemiplimab injected intralesionally in patients with recurrent CSCC. The secondary objectives of this study are: To describe the objective response rate (ORR) in CSCC index lesions following intralesional injections of cemiplimab in patients with recurrent CSCC, according to modified …

intralesional injection
measurable disease
cemiplimab
  • 1 views
  • 25 Jan, 2021
  • 9 locations